The Gut Microbiota from Lean and Obese Subjects Contribute Differently to the Fermentation of Arabinogalactan and Inulin by Aguirre, Marisol et al.
  
 University of Groningen
The Gut Microbiota from Lean and Obese Subjects Contribute Differently to the Fermentation
of Arabinogalactan and Inulin





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Aguirre, M., Bussolo de Souza, C., & Venema, K. (2016). The Gut Microbiota from Lean and Obese
Subjects Contribute Differently to the Fermentation of Arabinogalactan and Inulin. PLoS ONE, 11(7),
[0159236]. https://doi.org/10.1371/journal.pone.0159236
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
RESEARCH ARTICLE
The Gut Microbiota from Lean and Obese
Subjects Contribute Differently to the
Fermentation of Arabinogalactan and Inulin
Marisol Aguirre1,2,3, Carlota Bussolo de Souza3,4,5, Koen Venema1,2,6*
1 Top Institute of Food & Nutrition (TIFN), Wageningen, The Netherlands, 2 Maastricht University, School of
Nutrition and Translational Research in Metabolism (NUTRIM), Faculty of Health, Medicine and Life
Sciences, Department of Human Biology, Maastricht, The Netherlands, 3 The Netherlands Organization for
Applied Scientific research (TNO), Zeist, The Netherlands, 4 CNPq, Brasilia, Brazil, 5 University of




An aberrant metabolic activity or a compositional alteration of the gut microbiota has been
proposed as a factor that makes us more prone to disease. Therefore, we explored the
effect of two dietary fibers (arabinogalactan and inulin) on the microbiota from lean and
obese subjects during 72 h in vitro fermentation experiments using the validated TNO
dynamic in vitromodel of the proximal colon: TIM-2. Metabolically, arabinogalactan fermen-
tation showed a higher production of propionate when compared to n-butyrate in the obese
microbiota fermentations. In general, lean microbiota produced more n-butyrate from the
fermentation of both substrates when compared to the obese microbiota. Furthermore, the
obese microbiota extracted more energy from the fermentation of both fibers.
Results
Compositionally, bacteria belonging toGemmiger, Dorea, Roseburia, Alistipes, Lactobacil-
lus and Bifidobacterium genera were found to be highly abundant or stimulated by the pre-
biotics in the lean microbiota suggesting a potential role in leanness. Furthermore, a
significant correlation between known butyrogenic strains including B. adolescentis, an
unclassified Bifidobacterium and F. prausnitzii with this metabolite in the fermentation of
inulin in both microbiotas was found.
Conclusions
Although supplementary in vivo studies are needed, the current study provides more evi-
dence for the consumption of specific ingredients with the aim of modulating the gut micro-
biota in the context of obesity.
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Introduction
The discovery of the potential impact of the gut microbiota on human health and disease has
fuelled research on characterizing the role that this community plays in the causality or preven-
tion of many diseases elicited by dangerous lifestyles such as sedentary and bad eating habits,
among others [1, 2].
Part of the efforts have been focused on identifying a balanced and thus, healthy community
[3]. Though provocative, it is difficult to define a “most desirable” composition for the human
gut microbiota. Reports providing contradictory findings, due to either i) a large inter-individ-
ual variation or ii) the application of different analytic methods, are at the order of the day.
However, another factor which seems to play an important role in influencing health and dis-
ease, besides the community composition, is the interaction of the microbial metabolites with
the host.
The fermentation of dietary fiber by the gut microbiota leads primarily to the production of
short-chain fatty acids (SCFA; mainly acetate, propionate and butyrate) and the gases hydro-
gen, methane and carbon dioxide [4]. Furthermore, branched-chain fatty acids (BCFA; mainly
iso-butyrate and iso-valerate often accompanied by phenol and ammonia production) are also
produced to a lesser extent but these mostly originate from protein fermentation [5]. A pro-
posed mechanism by which fiber may protect us against obesity is based on the beneficial
effects that such metabolites have on host energy balance, e.g. by mediating the secretion of gut
hormones involved in the regulation of energy metabolism and food intake (including leptin,
peptide YY and glucagon-like peptide-1) [6, 7]. Thus, it may be tempting to say that high intake
of fiber would be a way to reduce the risk of obesity [8, 9]. After all, it is estimated that the pro-
duction of SCFA by the microbiota accounts for 5 to 10% of total dietary energy requirements
in humans [10]. However, recent research has questioned such risk-reduction role. There is
growing evidence indicating that the production of SCFA differs between the microbiota origi-
nating from obese and lean individuals (hereafter referred to as obese and lean microbiota).
Such difference lies in the fact that the obese microbiota may produce more SCFA which could
be translated into more energy extraction from diet [11, 12]. As a consequence, more energy
extracted from diet may be stored as fat, promoting host’s weight gain. Such mechanisms place
fiber fermentation by the gut microbiota as a causative factor in obesity. Still, as previously
remarked, there is a lack of consistency, different studies show contrasting results by finding
either no correlation between fiber and weight gain/obesity, a reverse trend or effects to be sub-
strate dependent [12–14].
Vast amounts of research are needed to answer the chicken or the egg causality dilemma
before any strategy can be designed with the aim of manipulating the gut microbiota in the
context of obesity. Currently, there is a limited number of in vitro fermentation experiments
mimicking the fermentation of different substrates by human obese or lean microbiota. So far,
these studies have provided evidence about the metabolic adaptation of the microbiota in rela-
tion to different nutrient loads or single testing of specific prebiotics, as well as the plasticity of
the microbiota in configuring the structure of the community in response to these kind of
interventions [14–19]. Importantly, these studies have also endorsed in vitro systems as tools
facilitating the medium to high-throughput validation of multiple hypotheses at lower costs
with no ethical constraints when compared to human or animal studies.
The purpose of the current study was to compare the profiles of fermentation of arabinoga-
lactan (AG) and the well-studied prebiotic inulin (IN) by obese or lean microbiota. Both AG
and IN are natural polysaccharides commonly found in foods. They have been found to be fer-
mented by human intestinal bacteria and stimulate the production of SCFA and the growth of
specific bacteria generally believed to be beneficial to the host [20–22]. AG is an interesting
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compound to evaluate not only because its potential to improve gut barrier function [23] but
also because it has been observed that it may induce production of (both pro and anti-inflam-
matory) cytokines [24, 25], factors which both may play an important role in inflammation. In
the context of obesity, low grade inflammation has been suggested to contribute to the develop-
ment of insulin and leptin resistance [26].
In order to compare the two prebiotics, we performed 72h fermentation experiments in the
validated TNO dynamic in vitromodel of the proximal colon (TIM-2), which was inoculated
with either obese or lean microbiota. The present work brings evidence about how fermentable
carbohydrates are differently used by the microbiota from lean and obese subjects which con-




The inocula used for the TIM-2 experiments consisted of an active, pooled fecal microbiota
prepared from: i) 8 healthy lean volunteers (male: n = 4, female: n = 4, average age = 31 y
(range: 25–42), BMI = 20 ± 1.48 kg/m2); ii) 7 healthy obese volunteers (male: n = 3, female:
n = 4, average age = 51 y (range: 29–68), BMI = 32 ± 1.17 kg/m2. We have previously shown
that pooling does not result in an aberrant microbiota composition or activity [27]. The exclu-
sion criteria for lean and obese volunteers included the use of antibiotics during the preceding
3 months, gastrointestinal disease, severe chronic disease or food allergy and intake of probiot-
ics and prebiotics.
Whole fecal samples were self-collected in a container kit which was maintained under
anaerobiosis by using anaerobic packs (AnaeroGen™, Oxoid, Cambridge, UK). A sample ali-
quot (100 mg) from each individual donation was collected in an anaerobic cabinet (80% N2,
10% CO2, 10% H2), snap-frozen in liquid nitrogen (-196°C) and stored at -80°C for measure-
ment of metabolites (SCFA and BCFA). Feces were homogenized under anaerobic conditions
as described by Aguirre et al. [28]. The resulting culture homogenate was aliquoted and snap-
frozen in liquid nitrogen. This microbiota was stored at -80°C before inoculation in TIM-2.
Gut fermentation experiments
The TIM-2 system was flushed with N2 prior to the introduction of the inoculum for 3 h and it
was maintained under this condition at 37°C for 96 h with the pH kept at or above 5.8 by auto-
matic titration with 2M NaOH. A 30 ml portion of culture homogenate was used to inoculate
the units for each experiment. The microbiota was left to adapt (16 h) to the new environment
after inoculation and during this period the basal simulated ileal efflux medium (SIEM) was
gradually introduced into the system in a total volume of 40 ml. After the adaptation, the cul-
ture was deprived from any medium for 2 h (starvation). A volume of 180 ml of the different
diets and control was administrated over the 72 h of the test period at a rate of 2.5 ml/h.
In order to remove water and fermentation products from the lumen, a dialysate system
(described in detail by van Nuenen et al. [29]), consisting of a semi-permeable hollow mem-
brane, ran through the lumen. For all the experiments, the speed of the dialysis fluid was set at
1.5 ml/ min.
After 24 and 48 h of fermentation 25 ml of lumen sample was removed from the system to
mimic the transit of material from the proximal and reaching the distal colon [30]. Luminal
and dialysate samples were taken after t = 0, 24, 48 and 72 h. In all cases samples were snap-fro-
zen in liquid nitrogen and stored (-80°C) until analysis.
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Fermentation media
During the adaptation period (16 h) all TIM-2 units were fed with SIEM as described by
Maathuis et al.[31]. After this adaptation period and the 2h starvation period, the units were
fed with preparations which were made containing approximately 7.5 g of AG or IN instead of
the standard carbohydrates in SIEM. The specific AG used in this study was (+)-Arabinogalac-
tan- from larch wood (Sigma-Aldrich, St Louis, USA) with a molecular weight ranging from
72–92 kDa and 84.8% purity. The IN tested had degree of polymerization (DP) of 9; 84.9%
> DP5 (Sensus, Frutafit1 IQ, Roosendaal, The Netherlands). Control experiments were per-
formed in parallel to the experiments testing either AG or IN. SIEM was used to feed the
microbiota in such controls.
Analysis of SCFA (acetate, propionate, and n-butyrate) and BCFA (iso-
butyrate and iso-valerate)
Samples were prepared and analyzed as described previously [14]. Before centrifuging, the
fecal aliquots from the individuals were suspended in PBS (1:1; w:w). Briefly, both suspended
aliquots and TIM-2 luminal samples were centrifuged (12000 r.p.m at 4°C for 10 min). To the
clear supernatant a mixture of formic acid (20%), methanol and 2-ethyl butyric acid (internal
standard, 2 mg/ml in methanol) was added. A 3 μl sample with a split ratio of 75.0 was injected
on a GC-column (ZB-5HT inferno, ID 0.52 mm, film thickness 0.10 um; Zebron; phenomenex,
USA) in a Shimadzu GC-2014 gas chromatograph. Standard curves were obtained by injecting
calibrated quantities of a blend of volatile fatty acids and amounts were calculated from the
graph obtained correlating peak height and time measured (all reagents from Sigma-Aldrich
with the exception of formic acid which was fromMerck).
Energy extraction
Energy extraction in the form of SCFA was calculated using the following kJ mol-1 values for
acetate, propionate and n-butyrate respectively: 874, 1536 and 2192 [32, 33].
Characterization of bacterial populations
RNA was isolated from luminal samples using standard molecular biology kits from ZYMO
Research (Zymo Research Co., CA, USA) following manufacturer’s instructions. Reverse-tran-
scriptase amplification of the 16S rRNA gene (V3-V4), barcoding and library preparation (1st
step PCR and 2nd PCR) were performed by BaseClear, Leiden, The Netherlands.
Short paired-end sequence reads were generated using the Illumina MiSeq system and con-
verted into FASTQ files using the BCL2FASTQ pipeline version 1.8.3. Quality trimming was
applied based on Phred quality scores. Subsequently, the Illumina paired reads were merged
into single reads (so-called pseudoreads) through sequence overlap (16S rRNA V3V4 region of
about 500bp). Chimeric pseudoreads were removed and the remaining reads were aligned to a
combination of the GreenGenes and RDP 16S gene databases [34, 35]. Based on the alignment
scores of the pseudoreads, the taxonomic classes were assigned by associating each pseudoread
to the best matching Operational Taxonomic Unit (OTU). The taxonomic depth of the lineage
is based on the identity threshold of the rank; Species 99%, Genus 97%, Family 95%, Order
90%, Class 85%, Phylum 80%.
Data analysis
The experiments were performed in series of two per tested substrate (n = 2). These replicates
were conducted for each microbiota (i.e. lean or obese). To avoid unnecessary repetition, this is
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not indicated further in the text or graphs in the results section. Results are displayed as average
of these duplicates. For simplicity of reading, substrates in the following sections are tagged
with the letter L or O (e.g. substrate-L, substrate-O) in order to refer to the fermentation exper-
iments using the inoculum from lean (-L) or obese (-O) subjects.
Statistical analyses for determining the differences in metabolite production and energy
extraction in the fecal samples from each individual were performed (SPSS for Windows, ver-
sion 21, SPSS, Chicago, US). Comparison between the two groups (lean and obese) was per-
formed using t-test with significance p<0.05.
For the calculation of fold compositional changes the ratio between a sampling time point
and t0 was calculated (i.e., t72/t0). Then the ratio for this value and the control was then deter-
mined to obtain fold changes. A value equal to 1 indicates no change; a value of>1 indicates
an increase; and a value of<1 indicates a decrease of the respective microbial genera.
A correlation analysis was performed in order to test if the metabolites measured would pos-
itively or negatively correlate with the different bacterial groups fed either with AG or IN. To
these means, differentially abundant bacterial species growing on the different tested substrates
were calculated from a ratio based from the specific growth of the species found on each sub-
strate and the control. Spearman correlations were calculated between the ratio of the species
identified as being differentially abundant and the measured amounts of metabolites produced
(SPSS for Windows, version 21, SPSS, Chicago, US). Correlations were considered significant
at the 0.01 level (2-tailed).
Ethics Statement
Studies using fecal donations from healthy volunteers do not require medical ethical committee
approval in The Netherlands since they are considered as non-invasive. However, volunteers
who donated the inoculum were informed prior to initiating the study and their participation
was considered after providing a signed informed consent. The group of obese donors were
recruited at Maastricht University Medical Center (The Netherlands). These were patients from
the university medical center who voluntarily responded to a recruiting call from inviting to
donate their feces. The group of lean donors were recruited at TNO (The Netherlands). These
participants responded to an advertisement inviting subjects to voluntarily collect their feces.
Bouke Salden and Carlota Bussolo de Souza personally collected the fecal samples from the par-
ticipants who exclusively donated their feces for the present study. Bouke Salden received the
fecal samples directly from the obese participants and none of the authors was involved in the
direct collection of these samples. Carlota Bussolo de Souza received the fecal samples directly
from the lean participants. The origins of the both lean and obese fecal donations were blinded
using a code whose identity was known only by the responsible scientist (Carlota Bussolo de
Souza, co-author of the present study). Results in this manuscript are referred to an individual
sample or a pool fecal inoculum and do not directly refer to a particular person.
Results
Screening of metabolites and energy extraction in feces from the
volunteers
The average amount of SCFA found in the feces from lean and obese subjects were not statisti-
cally different (259.6 ± 100.2 mmol and 215.1 ± 66.9 mmol, respectively). However, it was clear
that there was a great inter-individual difference regarding the amount of each SCFA in both
groups (S1 Table). When comparing the production of each SCFA and the amount of energy
extracted, no statistically significant differences were found.
in Vitro Fermentation of Arabinogalactan and Inulin
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BCFA were higher in the feces from lean volunteers (p<0.05). On average, lean subjects
produced 7.88 ± 2.54 mmol of iso-butyrate and 11.45 ± 3.64 mmol of i-valerate, while obese
subjects produced on average 3.11 ± 1.98 mmol of i-butyrate and 4.85 ± 2.92 mmol of i-valer-
ate. BCFA production also presented a great inter-individual difference among subjects.
Fermentation experiments with lean and obese microbiota
Microbial activity. Total SCFA production was higher in fermentations using the obese
microbiota when compared to the lean (Fig 1). Fermentation kinetics in terms of SCFA pro-
duction observed from both inocula differed in AG, IN and control experiments. Fermentation
of AG showed major differences in propionate and n-butyrate production compared to the
other fermentations, with propionate even higher than n-butyrate in the obese microbiota fer-
mentations. In general, n-butyrate production is higher in the lean fermentations for all sub-
strates when compared to obese, while propionate is observed to be higher in the fermentations
with the obese microbiota when compared to lean.
Table 1 shows the cumulative production of BCFA after 72 h of fermentation of AG, IN and
control. Lean microbiota produced more BCFA from AG fermentation and less from IN than
control. For AG this was also observed in the obese microbiota. The values from the obese fer-
mentations were lower when compared to lean for control and AG, but not for IN.
Energy extraction. The microbiota from obese volunteers fermenting AG and IN
extracted (slightly) more energy when compared to the lean fermentations, in accordance with
the higher SCFA production. Controls remained quite similar with respect to energy extraction
(Fig 2).
Fig 1. Cumulative production of SCFA (mmol) during the 72 h of fermentation of the tested substrates.
doi:10.1371/journal.pone.0159236.g001
Table 1. Cumulative production of BCFA after 72 h of fermentation of AG, IN and control.
Test Lean Obese
Compound i-butyrate i-valerate Total i-butyrate i-valerate Total
Arabinogalactan 1.62 ± 0.66 2.32 ± 0.08 3.94 ± 0.75 0.55 ± 0.36 1.59 ± 0.38 2.13 ± 0.74
Inulin 0.22 ± 0.2 1.23 ± 0.15 1.45 ± 0.35 0.45 ± 0.07 1.49 ± 0.08 1.94 ± 0.15
Control 0.74 ± 0.14 1.99 ± 0.4 2.73 ± 0.27 0.44 ± 0.28 1.22 ± 0.06 1.66 ± 0.22
doi:10.1371/journal.pone.0159236.t001
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Compositional changes. By calculating L/O ratios (at the genus level), it was found that
the lean microbiota had an increased relative abundance of Faecalibacterium (75 fold), Dorea
(30 fold), Roseburia (6 fold), Blautia (3 fold) when compared to the obese microbiota (S2
Table; for more information about the starting inocula refer to S1 Fig).
The fermentation of AG and IN resulted in the growth or decrease of specific genera.
Table 2 (AG) and Table 3 (IN) show the effects observed in the different microbiotas per sub-
strate tested, compared to the control.
Arabinogalactan. Genera that increased after the fermentation of AG by the obese microbiota
but decreased in the experiments with the lean microbiota are the well-studied: Lactobacillus (3
vs 0.49 fold), Dorea (14 vs 0.95 fold), Fusinibacter (17 vs 0.03 fold), Parabacteroides (10 vs 0.31
fold), Faecalibacterium (2 vs 0.35 fold), and Blautia (2 vs 0.84 fold). At the species level the
growth of B. longum was stimulated in the fermentation with the lean microbiota while it
decreased in the obese (2 vs 0.21 fold, respectively; S3 Table) this effect was opposite for L.
mucosae (0.50 vs 2 fold, respectively). When compared to the control, B. caccae and B. thetaio-
taomicron notably increased in the lean microbiota (44 and 7 fold, respectively) whilst the
growth of L. gasseri (12 fold) was stimulated in the fermentations with the obese microbiota.
Inulin. After the fermentation of IN by the obese microbiota an increase in Bifidobacterium
(2 vs 0.8 fold), Faecalibacterium (3 vs 0.97 fold), Blautia (5 vs 0.5 fold) and Fusicatenibacter (28
vs 0.2 fold) was observed with respect to the lean microbiota. The fermentation of IN promoted
the growth of B. adolescentis and unclassified Bifidobacterium in the obese microbiota when
compared to lean (5 vs 0.66 fold; 2 vs 0.76 fold, respectively; S3 Table). Enterococcus faecalis was
increased in the fermentations with the lean microbiota when compared to control (6 fold).
Modulatory effect of the substrates on activity and composition of the microbiota. Spe-
cies in general were found to be divided in two groups: species that were positively correlated
Fig 2. Energy extraction. Values for the individual SCFA and the sum (total) obtained after 72h fermentation experiments of AG, IN
and control using lean or obese microbiota.
doi:10.1371/journal.pone.0159236.g002
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Table 2. Relative change of bacterial genera after 72h of fermentation experiments of arabinogalactan







unclassiﬁed Clostridiaceae 0.37 1.29
unclassiﬁed Lactobacillaceae 0.25 3.70





unclassiﬁed Enterobacteriaceae 2.78 1.18







unclassiﬁed Bacteroidaceae 1.19 13.97
Fusicatenibacter 0.03 16.98
Parabacteroides 0.31 10.11
unclassiﬁed Peptostreptococcaceae 0.65 3.22
doi:10.1371/journal.pone.0159236.t002







unclassiﬁed Biﬁdobacteriaceae 1.09 1.83




unclassiﬁed Ruminococcaceae 0.98 3.27
unclassiﬁed Coriobacteriaceae 9.06 0.69
Blautia 0.49 4.53
unclassiﬁed Bacteroidaceae 2.62 0.88
Fusicatenibacter 0.21 27.99
unclassiﬁed Lachnospiraceae 0.73 2.50
doi:10.1371/journal.pone.0159236.t003
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with n-butyrate (found in O-inulin and L-inulin experiments) and species that were negatively
correlated to acetate, propionate and BCFA production (found in L-Inulin and L-arabino).
More specifically, correlation analysis performed showed a significant correlation of B. ado-
lescentis, unclassified Bifidobacterium, F. prausnitzii, an unclassified Faecalibacterium and an
unclassified Eubacterium with n-butyrate production; acetate, propionate and BCFA produc-
tion were also significantly correlated with F. prausnitzii and unclassified Faecalibacterium but
with an unclassified Bacteroides as well (Fig 3).
Discussion
The addition of fiber to food products has been proposed to reduce the caloric density and gly-
cemic impact of meals [36]. Therefore, there is growing interest in the use of functional fibers
in the form of food ingredients, additives or supplements in order to fortify the Western diet
without compromising the palatability of the food, especially in long-term weight management
programs [36, 37].
Other properties of dietary fiber have been well documented and it has been observed that it
exerts a wide array of biochemical, neurohormonal and microbiological effects in the human
body [36]. Here the gut microbiota, as a metabolic organ, has been found to be influenced by
fiber consumption.
The amount and type of dietary fibers consumed have a direct impact on the microbial fer-
mentation capacity [38]. In this respect, studies have found that the gut microbiota from obese
subjects could be more efficient in extracting energy from diet than lean subjects [11, 39, 40].
However, findings are controversial and it has been proposed that fermentation of fibers, and
consequently their health effects, may be substrate dependent. Substrate dependency could be
explained by the fact that dietary fibre reflects a heterogeneous group of compounds that differ
in their chemical structure and physico-chemical properties, therefore reflecting on different
physiological functions or health benefits [41, 42].
In this study, AG and IN were provided to the microbiota from lean or obese subjects and
72 h fermentation experiments were performed. The aim was to compare the differences in the
fermentation profiles of these two fibers with respect to microbiota composition, but particu-
larly with respect to production of the microbial metabolites SCFA, which are an energy source
for the host.
Fig 3. Correlation of metabolites and a subset of marker bacterial species.Rows correspond to bacterial species; columns correspond
to measured metabolites. Red and green denote positive and negative correlation, respectively. The intensity of the colors represents the
degree of association between taxa abundances and metabolites as measured by Spearman's correlations. ** indicate associations
significant at the 0.01 level (2-tailed).
doi:10.1371/journal.pone.0159236.g003
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Determination of fiber fermentation in humans and rats is a common approach to charac-
terize the capacity of the gut microbiota to ferment a specific substrate. However, these studies
are expensive, time consuming and in the case of rats the metabolic products yield from the fer-
mentation of several types of fiber have been found to be significantly lower when compared to
humans [43–45]. Moreover, studies in humans are limited because of the limited sampling
capacity (non-invasively only feces can be collected), while most of the SCFA produced are
taken up during transit of the chime through the colon (estimated at 95% of produced SCFA)
[46]. Here, we used the TIM-2 system as an alternative tool to animal and human studies. In
vitro systems simulating the large intestine have been validated and found to accurately predict
the fermentation of fibers in human subjects by presenting the same magnitude of the differ-
ences in SCFA production [43]. In the current study pooling of fecal samples was performed to
create a standardized microbiota which was subsequently frozen and stored. Both pooling [27]
and the impact of freezing [28] have been validated before.
However, besides the lack of host interactions in such in vitro systems, another limitation is
the characteristic variability of the microbiota used to inoculate the models, which is derived
from a group of donors.
Involving different participants in a study like the present one constitutes one of the factors
that influence the sometimes contradictory results in gut microbiota research. Still, the partici-
pants recruited for this study were considered according to their diet, consumption of prebio-
tics, probiotics and medication as specified in the M&M section. We considered including the
microbiota from only those volunteers who fitted the best for the requirements from the two
groups that we studied (i.e. lean and obese). Importantly, BMI index was prioritized given that
the main goal of this investigation was exploring the differences between lean and microbiota
fermenting AG and IN. We want to emphasize that the BMI index among subjects was very
similar. This was reflected by the low standard deviation value observed in both groups
(M&M). By setting the inclusion requirements mentioned above we believe that the outcome
of our studies are the result of a lean or obese microbiome phenotype. Still, we acknowledge
that the age difference from our group of volunteers might have contributed to differences in
the microbiota.
The current study provides more evidence for the consumption of specific ingredients with
the aim of modulating the gut microbiota in the context of obesity.
Impact of the substrates on metabolic activity
When compared against each other and against the control, both fibers presented different fer-
mentation kinetics (in terms of SCFA production) (Fig 1). The difference between the produc-
tion of propionate and n-butyrate in AG experiments using both microbiotas (S2 Fig) is
interesting in the light of the discussion of the impact of microbial metabolites in obesity. The
increase in propionate production in the experiments with the obese microbiota suggests that
via this metabolite AG could be protective against inflammation and promote satiety in obese
subjects.
Despite that most studies about the anti-inflammatory role of SCFA have been focused on
the effects of n-butyrate and acetate [47, 48], there is evidence pointing to propionate as a
metabolite with a strong role against inflammation [49]. On the one hand, propionate acts as a
ligand of G-protein-couple receptors (GPCR) 41 and 43 [50]. These receptors when activated,
induce an increase of GLP-1 (which slows down gastric emptying and promotes satiety) and
PYY (which up-regulates food digestion and absorption). Besides this, it has also been shown
that when they are absent (at least for GPCR43 in knockout mice) there is an exacerbated
inflammation in inflammatory-disease models [51]. Moreover, propionate has been found to
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decrease fatty acid levels in plasma [47]. As there is also evidence indicating that high plasma
levels of fatty acids cause inflammation and consequently insulin resistance, the postulation of
propionate as a molecule with anti-obesity properties is reinforced.
On the other hand, propionate has also been linked to autism [52] and hence, an increase in
this metabolite may not be desirable, although the mechanism is not entirely clear.
In this study, IN was found to increase the production of n-butyrate in the fermentations
with the lean microbiota (S2 Fig) when compared to the obese. The butyrogenic effect of IN
has been previously observed in vivo and in vitro [16, 18, 53–57]. n-Butyrate has been postu-
lated as a molecule with health benefits for the human host since it has been found to be an
important source of energy for colonocytes, with a potential protective role against colon can-
cer. In addition, it has been inversely correlated with inflammatory bowel diseases such as
Crohn’s disease [58–61]. To our knowledge only two studies have tested in vitro the fermenta-
tion of IN in both microbiotas (lean and obese). Both Sarbini et al [16] and Bussolo de Souza
et al [18] found that the obese fermentation of IN produced higher concentrations of n-buty-
rate when compared to the lean fermentation. The inocula composition is not the same all the
time (S2 Table) and that may have contributed to our results. Nevertheless, we have observed
that there are some compositional similarities in both inocula despite being prepared in differ-
ent years (S2 Table).
The fermentation of AG showed decreased BCFA concentrations in the fermentations with
the obese microbiota when compared the lean. This supports the work from Vince and col-
leagues [62] and Robinson & Slavin [20] who observed a significant decreased in products
from proteolytic fermentation (specifically ammonia) by intestinal bacteria after the supple-
mentation of AG. However, our study brings evidence, for the first time, about this beneficial
effect of AG in obese subjects.
Though production of BCFA was not lower in the obese microbiota fermenting IN when
compared to lean, at least, when it is compared to control, the fermentation of IN with the lean
microbiota is lower, giving also a good indication of the prebiotic effect of IN in ameliorating
proteolytic fermentation. This effect has been previously observed in vitro as well as in vivo [29,
63, 64].
Energy extraction
The hypothesis that the gut microbiota in obese individuals facilitates the additional extraction
of calories from diet has been previously reviewed [38, 65, 66]. In this study we were not able to
confirm that the energy yield (in terms of SCFA produced) was higher in the feces from the
obese donors in comparison with the lean donors (S1 Table). However, the absorption of
SCFA has been described as a very efficient process since only 5–10% is excreted in the feces
[67]. Furthermore, in a study performed by Jumpertz and colleagues [68] overfeeding in lean
subjects was associated with a greater decrease in stool energy loss showing a relation between
loss of energy in feces and energy load. Therefore, based on our results we could hypothesize
that obese individuals may have higher capacity of absorbing SCFA in their gut and, therefore,
may have lower amounts of these metabolites in their feces compared with lean subjects.
However, we found a substrate dependent effect on the metabolic activity and consequently
energy extraction when fermentation of both AG and IN were performed. These findings con-
firm our previous observations where a higher amount of energy extracted from the fermenta-
tion of IN was also found after fermentation by obese microbiota when compared to lean [18].
Although the difference is small, over a prolonged period this may add up to several kilos of
body weight, since, as previously mentioned, an elevated production of SCFA contributes to a
higher energy input to the host. But at the same time these metabolites have also been found to
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present satiety-enhancing properties via the activation of GPCRs. Thus, it could be that the
enhancement of the production of these metabolites could be protective against obesity in this
population, despite their energy content. Still, more research is needed in this area.
Compositional changes
When the inocula prepared from both lean and obese subjects (previous study; 2012) is com-
pared to the inocula from the present study (2014), we observed some compositional differ-
ences in the shared bacterial groups. This shows that not all inocula are the same. However,
there are some similarities in some increased groups observed from the L/O ratios (S2 Table)
making it possible to distinguish certain bacteria belonging for example to Gemmiger, Dorea,
Roseburia, Alistipes genera which both times were highly abundant in the lean microbiota and
deserve being more investigated about their potential role in leanness.
After fermenting AG by the different microbiota the growth of some groups of bacteria was
highly stimulated in one microbiota whilst they decreased in the other. Between the groups
that were benefited from the fermentation of AG in the obese microbiota we found Faecalibac-
terium, Dorea and Blautia. Judging from the ratios calculated in order to compare both inocula
(L/O 2014; S2 Table), it seems that the community from obese donors tend to re-structure
towards the microbiota from lean donors after the fermentation of AG (Table 2).
This effect was also previously observed by Bussolo de Souza et al [18] and Condezo-Hoyos
et al [19] when testing the prebiotic effects of cassava bagasse and different apple cultivars on
the composition from lean and obese microbiota.
Lactobacillus was observed to increase in the obese microbiota fermenting AG (Table 2).
Furthermore, we also described an increase of the species L.mucosae and L.gasseri in the obese
microbiota after fermenting AG. Our results are in agreement with Robinson & Slavin [20]
when showing that a diet supplemented with AG increased the concentration of Lactobacillus
in the feces from healthy participants. In addition, a study conducted by Santacruz et al [69]
showed a parallel reduction of body mass index (BMI) and increase of Lactobacillus spp. con-
centrations in obese adolescents suggesting a potential role of this genera in obesity and body
weight control. Based on these findings we suggest that our study brings more evidence about
how a prebiotic such as AG can beneficially influence the composition of the microbiota from
obese subjects in weight management.
The lean microbiota fermenting AG presented an increase in B. thetaiotaomicron. The
growth of this species on AG has also been found by others [70]. B. thetaiotaomicron coloniza-
tion has been observed to elicit gene expression involved with the fortification of the intestinal
barrier function and the maintenance of mucosal integrity which may suggest to be specially
beneficial in obese subjects [71].
The obese microbiota composition on IN shifted the simulated gut environment into a
more healthy milieu with increase of beneficial bacteria belonging to the Faecalibacterium,
Blautia, Fusicatenibacterium and Bifidobacterium genera. The bifidogenic effect of IN was
demonstrated to be more pronounced in the obese microbiota when compared to lean
(Table 3). Interestingly, this effect was shown to selectively stimulate the growth of B. adoles-
centis (S4 Table). This is in agreement with the upregulation of B. adolescentis by IN also found
by Ramirez-Farias et al [22] and B.animalis by Venema and Maathuis [72]. In fact the latter
authors hypothesized that within the Bifidobacterium genus, the diversity was diminished by
inulin. This was also observed to some degree in our experiments (S4 Table).
The difference in the bifidogenic effect of IN in the obese microbiota, especially in the spe-
cific case of B. adolescentis growth, can be explained by i) a long-known inverse relation
between initial amounts present and the observed increase [73]. As observed e.g. by Korpela
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et al [74] and other authors, the lower the abundance of Bifidobacterium spp. at the starting
point of an intervention, the more the increase observed after the administration of an specific
prebiotic, and vice versa [74–76]; or ii) the high specificity of IN for stimulating the growth of
certain bifidobacterial species as observed by Venema &Maathuis [72]. A high abundance of
bifidobacteria could be protective in obesity since it is speculated that this bacteria may
decrease pro-inflammatory cytokines and decrease endotoxaemia which can improve glucose-
induced insulin and glucose tolerance [16, 77].
Conclusion
First line strategies to combat obesity include exercise and/or a balanced dietary regime. Though
apparently simple, such changes in people’s life are difficult to maintain and in most of the cases
patients struggle to follow these recommendations. Due to the complexity of this condition, it is
vital to identify weight loss methods by which subjects can successfully achieve long-term
results. In this respect, using fibers is a potential tool to supplement diet in weight management
due to their satiety aspects, as well as in modulating the gut microbiota. Here in this study we
have identified the potential of arabinogalactan and inulin in stimulating a gut community
more related to a lean profile. Metabolically, arabinogalactan fermentation showed a higher pro-
duction of propionate when compared to n-butyrate in the obese microbiota fermentations. In
general, lean microbiota produced more n-butyrate from the fermentation of both substrates
when compared to the obese microbiota. This would be interesting to investigate in light of the
potential activation of different GPCRs by these SCFA. However, these effects should be more
studied in humans focusing especially in the role of these fibers in satiety.
Supporting Information
S1 Fig. Abundance (%) of the major groups of genera in the microbiota from lean and
obese subjects. At genus level, it was observed that differences among the inocula are driven by
the abundances within the same groups of bacteria (S1 Fig). The major groups in the lean
microbiota were Bifidobacterium, Clostridium, Lactobacillus and Enterococcus (23, 34, 14 and
13%, respectively) and in the obese microbiota were Clostridium, Lactobacillus, Enterococcus,
Bifidobacterium (46, 17, 15 and 10%). Analysis of the species found in the inoculum (t0) sug-
gests that the lean microbiota has a more diverse population of Bifidobacterium which included
B. adolescentis, B. longum and an unclassified group (7, 4 and 8%, respectively) whilst the obese
microbiota mainly contains B. longum and an unclassified group (6 and 3%, respectively). Both
microbiotas share a high abundance of C. butyricum (lean: 23%; obese: 30%).
(TIF)
S2 Fig. SCFA ratios (%) from the different diets at t72.
(TIF)
S1 Table. Metabolites and energy extraction (in terms of SCFA) measured in the feces from
the volunteers.
(XLSX)
S2 Table. Ratio L/O. Relative ratio of bacterial genera different between lean and obese at t0 in
TIM-2.
(XLSX)
S3 Table. Relative change of bacterial species after 72h of fermentation experiments of ara-
binogalactan and inulin in TIM-2 using microbiota from lean and obese individuals.
(XLSX)
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S4 Table. Bifidobacterium species abundance from the fermentation of inulin. In both
cases (L and O-fermentations) B.adolescentis dominated the Bifido species after 72 h. In lean
microbiota a complete domination is observed while in the obese microbiota it is about 25 fold
higher (whereas at the start it was only ~8%). Previous testing of the in vitro effects of IN fer-
mentation in both microbiotas (lean and obese) found that the obese fermentation of IN pro-
duced higher concentrations of n-butyrate when compared to the lean fermentation [16, 18].
The difference with our study could be explained by the different stimulation of certain butyro-
genic strains which in this particular case found more favourable to growth in the lean micro-
biota as observed in S3 and S4 Tables.
(XLSX)
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